Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Hisun Licenses Novel Flu Treatment from Fujifilm

publication date: Jun 30, 2016
Zhejiang Hisun Pharma acquired China rights for a novel flu treatment from Japan's Fujifilm. Hisun will develop, manufacture and market favipiravir in China. In return, Fujifilm will receive a lump-sum payment and royalties on sales, neither of which was disclosed. Two years ago, favipiravir was approved for use in Japan. It is thought to have efficacy against avian flu strains and Ebola, and could become an important drug should either one reach pandemic proportions. More details....

Stock Symbol: (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital